Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | PLCD1 |
| Gene Name: | PLCD1 |
| Protein Full Name: | 1-phosphatidylinositol-4,5-bisphosphate phosphodie |
| Alias: | Phosphoinositide phospholipase C; Phospholipase c, delta 1; Phospholipase c, delta 1 isoform 1; Phospholipase c, delta 1 isoform 2; Phospholipase c, delta 1 variant; Phospholipase C-delta-1; Plcd1; PLC-III |
| Mass (Da): | 85646 |
| Number AA: | 756 |
| UniProt ID: | P51178 |
| Locus ID: | 5333 |
| COSMIC ID: | PLCD1 |
| Gene location on chromosome: | 3p22.2 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19718 |
| Percent of cancer specimens with mutations: | 0.5 |
| Normal role description: | PLCD1is a phospholipase that catalyzes the hydrolysis of PIP2 to DAG and IP3, both are secondary messengers used in signalling. In gastric, breast and esophageal cancers PLCD1 expression is reduced and associated with increased proliferation and migration. |